BioScrip (BIOS) Misses Q2 EPS by 14c, Revs Modestly Lower; Reiterates Outlook

BioScrip (NASDAQ: BIOS) reported Q2 EPS of ($0.26), $0.14 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $218.1 million versus the consensus estimate of $220.17 million.

2017 Guidance

The Company is reiterating its prior guidance of adjusted EBITDA in the range of $45.0 million to $55.0 million for full-year 2017. The Company is updating its revenue outlook for the year to a range of $815.0 million to $835.0 million, including the impact of the revised UnitedHealthcare contract. Additionally, the Company expects to incur restructuring expenses in a range of $11.0 million to $12.0 million, reflecting the ongoing restructuring activity that took place in the second quarter of 2017, and further expenses anticipated in the second half of 2017 primarily related to the impact of the revised UnitedHealthcare contract.

For earnings history and earnings-related data on BioScrip (BIOS) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• RegenLab targets Nasdaq listing under ticker RGNA as revenues top $29 million
• Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance